Twiist Users Mostly Hit Glucose Targets, Study Finds
A real-world analysis of 4,000 twiist automated insulin delivery users found most achieved target glucose metrics.
Updated on Nov. 4, 2026 in Diabetes
Live Poll
If you have diabetes and use insulin, would you consider an automated insulin delivery system?
An analysis of 4,000 people with type 1 or type 2 diabetes using the twiist automated insulin delivery system found most reached target glucose metrics. The data, covering April 29, 2025, to April 29, 2026, was published in Diabetes Technology & Therapeutics.
Why it matters
Real-world data on automated insulin delivery helps clinicians and patients understand how these systems perform outside controlled trials. The results suggest the technology can support glucose control across both type 1 and type 2 diabetes.
The analysis drew on real-world data from 4,000 users, who spent 97.7% of time in closed-loop mode and averaged 73.5% overall time in range. Its findings reflect app-tracked use over at least two weeks rather than long-term clinical outcomes.
The players
Viral Shah
Viral Shah is a researcher affiliated with the Indiana University Center for Diabetes and Metabolic Diseases, who led the analysis of twiist user data.
Indiana University Center for Diabetes and Metabolic Diseases
The Indiana University Center for Diabetes and Metabolic Diseases is an academic research center focused on diabetes care and metabolic disease study.
The details
Researchers analyzed data from twiist users, including children and adults with type 1 or type 2 diabetes, tracked for at least two weeks. Mean overnight time in range was 77.9%, while 86% of users spent under 4% of time below range.
Timeline
April 29, 2025: Start of the twiist user data collection period.
April 29, 2026: End of the twiist user data collection period.
November 4, 2026: Results published on Healio.
Health Landscape
The analysis adds real-world evidence to the growing field of automated insulin delivery systems, which have been studied mainly in controlled trials. Its focus on both type 1 and type 2 users reflects a broader push to extend these tools beyond the population they were first designed for.
For people with type 1 or type 2 diabetes considering automated insulin delivery, the findings show most users in this group reached glucose targets over a few weeks of use. Readers should discuss device options and expected results with their own clinicians before making changes.
The takeaway
Real-world data suggests automated insulin delivery can help many people with diabetes reach glucose targets. Individual results will vary, so care decisions should be made with a healthcare provider.
Further reading
Explore more on Diabetes for background on insulin delivery and glucose management.
Source note: This article includes information reported by Healio.
Live Poll
If you have diabetes and use insulin, would you consider an automated insulin delivery system?
